StockPriceToday

Gossamer Bio Inc. (GOSS)

GOSS stock price

Gossamer Bio Inc. (GOSS) is a biotechnology company developing innovative therapeutics for immunology, oncology, and other specialty medical conditions.

About Gossamer Bio Inc.

Gossamer Bio operates as a clinical-stage biotechnology company focused on developing innovative therapeutic candidates for immunology, oncology, and other specialty conditions through targeted drug discovery and development programs. The company's pipeline includes novel small molecules and other therapeutic modalities designed to address specific disease mechanisms and unmet medical needs across various therapeutic areas. Their research approach emphasizes mechanistic understanding, clinical validation, and strategic development of differentiated therapeutic candidates. GOSS stock price performance reflects clinical trial progress, regulatory developments, and the company's advancement of therapeutic candidates through development phases.

In the competitive biotechnology sector, Gossamer Bio has established differentiation through experienced leadership, focused therapeutic areas, and disciplined development approaches that emphasize clinical proof-of-concept and strategic value creation. The company competes with established pharmaceutical companies and emerging biotechnology firms while maintaining focus on high-potential therapeutic opportunities where innovation can address significant medical needs. Market positioning emphasizes scientific rigor, clinical execution, and strategic partnerships that enhance development capabilities and commercial potential. GOSS stock price movements often correlate with clinical data releases, partnership developments, and broader biotechnology sector sentiment.

Gossamer Bio's leadership team includes accomplished pharmaceutical executives and scientific experts who bring extensive experience in drug development, clinical research, and biotechnology commercialization to guide the company's strategic direction. Management has successfully advanced multiple therapeutic candidates through clinical development while maintaining disciplined resource allocation and strategic focus on high-value opportunities. The executive team's development expertise and strategic vision position Gossamer Bio to capitalize on breakthrough therapy opportunities and partnership possibilities, with leadership decisions regarding pipeline prioritization and development strategies significantly influencing investor expectations and long-term value creation potential.

GOSS Stock 12 Month Chart


Latest News for GOSS

Second-quarter revenue reached USD 9.24 million in Q2 2026. Gossamer Bio stock had a USD 54.3 million market value on October 15, 2026. Gossamer Bio submitted its first NDA for seralutinib on ...

Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a ...

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...